OM:ISR

Stock Analysis Report

ISR Immune System Regulation Holding

Executive Summary

ISR Immune System Regulation Holding AB (publ) researches and develops drugs for treatments of viral infections in Sweden.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Risks

  • ISR Immune System Regulation Holding has significant price volatility in the past 3 months.
  • ISR Immune System Regulation Holding is not covered by any analysts.

Share Price & News

How has ISR Immune System Regulation Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-18.6%

OM:ISR

-3.2%

SE Biotechs

-1.3%

SE Market


1 Year Return

17.7%

OM:ISR

-19.7%

SE Biotechs

-2.7%

SE Market

ISR outperformed the Biotechs industry which returned -19.5% over the past year.

ISR outperformed the Market in Sweden which returned -3.1% over the past year.


Share holder returns

ISRIndustryMarket
7 Day-18.6%-3.2%-1.3%
30 Day-28.8%-9.2%-4.7%
90 Day-34.4%-3.6%-2.9%
1 Year19.0%17.7%-19.4%-19.7%1.4%-2.7%
3 Yearn/a41.8%30.9%25.3%6.6%
5 Yearn/a52.2%50.9%44.9%14.3%

Price Volatility Vs. Market

How volatile is ISR Immune System Regulation Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ISR Immune System Regulation Holding undervalued based on future cash flows and its price relative to the stock market?

4.56x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for ISR Immune System Regulation Holding to establish if it is available at moderate discount.

Unable to calculate intrinsic value for ISR Immune System Regulation Holding to establish if it is available at substantial discount.


Price Based on Earnings

ISR Immune System Regulation Holding is loss making, we can't compare its value to the SE Biotechs industry average.

ISR Immune System Regulation Holding is loss making, we can't compare the value of its earnings to the Sweden market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ISR Immune System Regulation Holding, we can't assess if its growth is good value.


Price Based on Value of Assets

ISR Immune System Regulation Holding is overvalued based on assets compared to the SE Biotechs industry average.


Next Steps

Future Growth

How is ISR Immune System Regulation Holding expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.0%

Forecasted Biotechs industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ISR Immune System Regulation Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has ISR Immune System Regulation Holding performed over the past 5 years?

1.2%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ISR Immune System Regulation Holding does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare ISR Immune System Regulation Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ISR Immune System Regulation Holding's 1-year growth to the SE Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ISR Immune System Regulation Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ISR Immune System Regulation Holding has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ISR Immune System Regulation Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ISR Immune System Regulation Holding's financial position?


Financial Position Analysis

ISR Immune System Regulation Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ISR Immune System Regulation Holding's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ISR Immune System Regulation Holding has no debt.

ISR Immune System Regulation Holding currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

ISR Immune System Regulation Holding has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ISR Immune System Regulation Holding has sufficient cash runway for 1.9 years based on current free cash flow.

ISR Immune System Regulation Holding has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of -4.6% each year.


Next Steps

Dividend

What is ISR Immune System Regulation Holding's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ISR Immune System Regulation Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ISR Immune System Regulation Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ISR Immune System Regulation Holding has not reported any payouts.

Unable to verify if ISR Immune System Regulation Holding's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ISR Immune System Regulation Holding has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of ISR Immune System Regulation Holding's salary, the management and board of directors tenure and is there insider trading?


CEO

ISR Immune System Regulation Holding has no CEO, or we have no data on them.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team


    Board Members

      Company Information

      ISR Immune System Regulation Holding AB (publ)'s company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: ISR Immune System Regulation Holding AB (publ)
      • Ticker: ISR
      • Exchange: OM
      • Founded:
      • Industry: biotechnology
      • Sector: pharmaceuticals & biotech
      • Market Cap: kr128.040m
      • Shares outstanding: 24.72m
      • Website: Click here

      Location

      • ISR Immune System Regulation Holding AB (publ)
      • Rörstrandsgatan 58
      • Stockholm
      • Stockholm County
      • 113 40
      • Sweden

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      ISROM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKMar 2017

      Biography

      ISR Immune System Regulation Holding AB (publ) researches and develops drugs for treatments of viral infections in Sweden. Its product candidates include ISR048 that is in Phase I/IIa clinical trial for th ...


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2019/08/16 22:07
      End of Day Share Price2019/08/16 00:00
      Earnings2018/12/31
      Annual Earnings2018/12/31


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.